In 2009, our group demonstrated that hepatocyte growth factor receptor (MET) oncogene, through Jun transcriptional activation, upregulated miR-221 and -222 expression, which in turn, by targeting PTEN and TIMP3, conferred resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced cell death and enhanced tumorigenicity of lung and liver cancer cells. This evidence concerns the gene MET and liver cancer.